Migraine is a common disabling neurological disorder, often starting in children and adolescents. Triptans, a class of selective 5HT1b/d receptor agonists, have been shown to be effective and well-tolerated as acute therapy in adult migraineurs.
Data examining efficacy and tolerability of triptans in adolescents are limited compared with adults.
Almotriptan has recently been approved by the USA regulatory authorities (FDA) for the acute treatment of migraine headache in adolescent patients (age 12 to 17 years).
A double-blind placebo-controlled, parallel group, multicenter trial demonstrated that oral almotriptan in effective and well tolerated in adolescents, with the 12,5 mg dose associated with the most favourable profile. The aim of this review is to give an overview of clinical data about efficacy and safety of oral Almotriptan in adolescents.
RIS citation (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)
BibTex citation (BIBDESK, LATEX)
I have had nothing but positive experiences publishing with Libertas Academica. The publication procedure is as quick and smooth as any I've encountered, and the peer review process is sufficiently rigorous that the reader can have complete confidence in the content of its journals.
All authors are surveyed after their articles are published. Authors are asked to rate their experience in a variety of areas, and their responses help us to monitor our performance. Presented here are their responses in some key areas. No 'poor' or 'very poor' responses were received; these are represented in the 'other' category.See Our Results
Copyright © 2013 Libertas Academica Ltd (except open access articles and accompanying metadata and supplementary files.)